Tirzepatide is a next-generation peptide being studied for its dual action on GLP-1 and GIP receptors, with potential to support weight loss, improve insulin sensitivity, and enhance metabolic health.
Refill Program Details
One refill per month for 6 months
Benefits
May improve insulin sensitivity
May enhance weight loss
May help regulate blood sugar levels
May reduce inflammation
May increase metabolic rate
Dosing
Microdose: 250-500mcg
Basic Dosing: 2.5mg up to 10mg once weekly
CONSULT NEEDED FOR TITRATION SCHEDULE
Microdose: add 4mL BAC to the vial of Tirzepatide 10mg
Draw 10 units (0.1mL) for a dose of 250mcg
Draw 20 units (0.2mL) for a dose of 500mcg
Draw 40 units (0.4mL) for a dose of 1mg
Basic Dosing: add 4mL BAC water to vial of Tirzepatide 10mg
Draw 100 units (1mL) for a dose of 2.5mg (initiation dose)
Draw 200 units (2mL) for a dose of 5mg
How to Use
Duration: 6 months
Once a week, on the same day each week
Subcutaneous injection
Reconstitute: add 4mL’s of bacteriostatic water to the 10mg vial of Tirzepatide
MOA
Dual Incretin Receptor Agonism:
Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Through coordinated activation of these incretin pathways, Tirzepatide enhances metabolic efficiency, glucose regulation, and energy balance.
GLP-1 Receptor Activation:
Stimulation of GLP-1 receptors increases glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying. These actions collectively reduce postprandial glucose excursions while promoting satiety and appetite control through hypothalamic signaling.
GIP Receptor Activation:
Concurrent activation of GIP receptors amplifies glucose-stimulated insulin release and supports lipid metabolism. This mechanism also contributes to improved insulin sensitivity and may preserve pancreatic β-cell function under metabolic stress.
Synergistic Incretin Effects:
The combined engagement of GLP-1 and GIP receptors produces additive and synergistic metabolic benefits. These include enhanced glucose utilization, reduced insulin resistance, and greater weight reduction compared to selective GLP-1 receptor agonism alone.
Metabolic and Lipid Regulation:
Tirzepatide improves overall metabolic function by enhancing peripheral glucose uptake and optimizing lipid oxidation. These effects contribute to improved body composition and cardiovascular risk reduction.
Energy and Weight Homeostasis:
By integrating hormonal signaling from both incretin pathways, Tirzepatide effectively lowers appetite, improves energy expenditure, and promotes sustained weight management while maintaining glycemic stability.
More Information
Disclaimer: For Research Purposes Only – All products on this site are for Research and Development use only. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. Celia Health is a supplier of research-use chemicals manufactured in a CGMP facility in the US. Celia Health is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act.
This product requires a prescription. After purchasing, you will receive instructions to schedule and complete your intake exam before your order can be fulfilled. Prescriptions are valid for one calendar year.